These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9527400)

  • 1. Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome.
    Drukker A; Eddy AA
    J Am Soc Nephrol; 1998 Feb; 9(2):243-51. PubMed ID: 9527400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis.
    Lee HS; Jeong JY; Kim BC; Kim YS; Zhang YZ; Chung HK
    Kidney Int; 1997 Apr; 51(4):1151-9. PubMed ID: 9083281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant.
    Magil A
    J Am Soc Nephrol; 1996 Nov; 7(11):2340-7. PubMed ID: 8959623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
    Hirano T; Mamo JC; Nagano S; Sugisaki T
    Nephron; 1991; 58(1):95-100. PubMed ID: 1857487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis.
    Hirano T; Morohoshi T
    Nephron; 1992; 60(4):443-7. PubMed ID: 1584321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats.
    Jones CL; Buch S; Post M; McCulloch L; Liu E; Eddy AA
    Am J Pathol; 1992 Dec; 141(6):1381-96. PubMed ID: 1281619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.
    El-Swefy S; Schaefer EJ; Seman LJ; van Dongen D; Sevanian A; Smith DE; Ordovas JM; El-Sweidy M; Meydani M
    Atherosclerosis; 2000 Apr; 149(2):277-86. PubMed ID: 10729377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dietary antioxidants on puromycin aminonucleoside nephrotic syndrome.
    Pedraza-Chaverri J; Arévalo AE; Hernández-Pando R; Larriva-Sahd J
    Int J Biochem Cell Biol; 1995 Jul; 27(7):683-91. PubMed ID: 7648424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein restriction reduces transforming growth factor-beta and interstitial fibrosis in nephrotic syndrome.
    Eddy AA
    Am J Physiol; 1994 Jun; 266(6 Pt 2):F884-93. PubMed ID: 8023968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeine augments proteinuria in puromycin-aminonucleoside nephrotic rats.
    Tofovic SP; Rominski BR; Bastacky S; Jackso EK; Kost CK
    Ren Fail; 2000 Mar; 22(2):159-79. PubMed ID: 10803761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interstitial fibrosis in hypercholesterolemic rats: role of oxidation, matrix synthesis, and proteolytic cascades.
    Eddy AA
    Kidney Int; 1998 May; 53(5):1182-9. PubMed ID: 9573532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid lowering: an important factor in preventing adriamycin-induced heart failure.
    Iliskovic N; Singal PK
    Am J Pathol; 1997 Feb; 150(2):727-34. PubMed ID: 9033285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicorandil protects podocytes via modulation of antioxidative capacity in acute puromycin aminonucleoside-induced nephrosis in rats.
    Yamanaka M; Tamura Y; Kuribayashi-Okuma E; Uchida S; Shibata S
    Am J Physiol Renal Physiol; 2023 Feb; 324(2):F168-F178. PubMed ID: 36454699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis.
    Jones CL; Buch S; Post M; McCulloch L; Liu E; Eddy AA
    Kidney Int; 1991 Dec; 40(6):1020-31. PubMed ID: 1762303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats.
    Kawamorita Y; Shiraishi T; Tamura Y; Kumagai T; Shibata S; Fujigaki Y; Hosoyamada M; Nakagawa T; Uchida S
    Physiol Rep; 2017 Aug; 5(15):. PubMed ID: 28774949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of clofibrate on fatty acid metabolism in the kidney of puromycin-induced nephrotic rats.
    Muroya Y; Ito O
    Clin Exp Nephrol; 2016 Dec; 20(6):862-870. PubMed ID: 26949064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary vitamin E supplementation ameliorates renal injury in chronic puromycin aminonucleoside nephropathy.
    Trachtman H; Schwob N; Maesaka J; Valderrama E
    J Am Soc Nephrol; 1995 Apr; 5(10):1811-9. PubMed ID: 7787149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats.
    Park YS; Guijarro C; Kim Y; Massy ZA; Kasiske BL; Keane WF; O'Donnell MP
    Am J Kidney Dis; 1998 Jan; 31(1):190-4. PubMed ID: 9428473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome.
    Eddy AA; McCulloch L; Liu E; Adams J
    Am J Pathol; 1991 May; 138(5):1111-23. PubMed ID: 2024704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study.
    Haas M; Mayer G; Wirnsberger G; Holzer H; Ratschek M; Neyer U; Neuweiler J; Kramar R; Schneider B; Breiteneder-Geleff S; Regele HM; Hörl WH; Kerjaschki D
    Wien Klin Wochenschr; 2002 Feb; 114(4):143-7. PubMed ID: 12060980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.